Clinical Trials | October 09, 2022
Pfizer announces positive topline results from Phase 3 TALAPRO-2 trial
Study achieves primary endpoint of radiographic progression-free survival
Study achieves primary endpoint of radiographic progression-free survival
Transformation to pure-play Innovative Medicines company nears completion
RYALTRIS is a fixed-dose combination therapy that provides relief for the symptoms of SAR, both nasal and ocular, in one easy-to-use nasal spray
Nutrigenomics is the study of how genes and diet (nutrients) interact. Gene variants (genetic differences) predict how an individual’s body will respond to certain nutrients.
Results demonstrated a 64.5% confirmed objective response rate in patients treated with investigational combination of enfortumab vedotin and pembrolizumab
In first-line metastatic NSCLC, KEYTRUDA-based regimens have now shown a five-year survival benefit in four trials
On the precision oncology front, expanded larotrectinib data will focus on efficacy and safety findings for pediatric and adult patients with NTRK gene fusion-positive solid tumors
This launch builds upon Hikma’s leading position as one of the largest US providers of nasally administered medicines used for treating seasonal allergies and advances its objective of growing its specialty business in the US
Longer-term survival results underscoring role of KEYTRUDA (pembrolizumab) in multiple cancer types, including advanced nonsquamous non-small cell lung cancer (KEYNOTE-189)
New mass spectrometry instrument and consumables launch during IMSC 2022
Subscribe To Our Newsletter & Stay Updated
